References
1. Hogan P, Dall T, Nikolov P. American Diabetes Association: economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917–932.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
4. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol1995;75:894–903.
5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412.
6. American Diabetes Association. Standards of medical care for patients with diabetes mellitus.Diabetes Care 2003;26(Suppl 1):S33–S50.
7. Beckles GL, Engelgau MM, Narayan KM, et al. Population-based assessment of the level of care among adults with diabetes in the US. Diabetes Care 1998;21:1432–1438.
8. Harris MI. Medical care for patients with diabetes: epidemiologic aspects. Ann Intern Med1996;124:117–122.
9. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195–2000.
10. Janes GR. Ambulatory medical care for diabetes, in Harris MI, Cowie CC, Ster MP, et al (eds):Diabetes in America. 2nd ed. National Institutes of Health, Publication No. 95–1468, Bethesda, MD, 1995, pp 541–551.
11. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care2000;23:390–404.
12. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med1996;124:164–169.
13. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997;127:788–795.
14. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000;283:889–896.
15. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421–426.
16. Richardson WC, Berwick DM, Bisgard JC, et al: To err is human: building a safer health system. Institute of Medicine Report 1999; November. Retrieved February 19, 2004 from
http://www.nap.edu/books/0309068371/html
17. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet2002;360:7–22.
18. Fertig BJ, Simmons DA, Martin DB. Therapy for diabetes, in Harris MI, Cowie CC, Ster MP, et al (eds): Diabetes in America. 2nd ed. National Institutes of Health. Publication No. 95–1468, Bethesda, MD, 1995, pp 519–540.
19. Boccuzzi SJ, Wogen J, Fox J, et al. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care 2001;24:1411–1415.
20. Emslie-Smith AM, Boyle DI, Evans JM, et al. Contraindications to metformin therapy in patients with Type 2 diabetes: a population-based study of adherence to prescribing guidelines. Diabet Med2001;18:483–488.
21. Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003;290:81–85.
22. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990–2001. Diabetes Care 2003;26:1852–1855.
23. Meinert CL, Knatterud GL, Prout TE, et al: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, II: mortality results. Diabetes1970;19(Suppl 2):789–830.
24. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
25. Deutsch E, Berger M, Kussmaul WG, et al. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. Circulation1990;82:2044–2051.
26. Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol1994;24:1133–1142.
27. Riddle MC. Editorial: sulfonylureas differ in effects on ischemic preconditioning: is it time to retire glyburide? J Clin Endocrinol Metab 2003;88:528–530.
28. Lee T-M, Chou T-F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88:531–537.
29. Van den Berghe G, Wouters M, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359–1367.
30. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57–65.
31. Koproski J, Pretto Z, Poretsky L. Effects of an intervention by a diabetes team in hospitalized patients with diabetes. Diabetes Care 1997;20:1553–1555.
32. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004;27:553–591.